课题基金 / 基金详情

CD4 AND CORECEPTORS IN HIV-1/AIDS

CD4 AND CORECEPTORS IN HIV-1/AIDS
HIV-1/AIDS 中的 CD4 和辅助受体
批准号:
6626657
负责人:
David Kabat
金额:
$28.44万
依托单位国家:
美国
项目类别:
财政年份:
1995
资助国家:
美国
项目状态:
已结题
起止时间:
1995-03-15 至 2004-04-14

项目摘要

项目成果

David Kabat的其他基金

相似基金

相关文献

中文摘要
翻译
描述:(改编自调查人员摘要)这一目标 项目是对原发患者(PR)的感染进行量化分析 和实验室适应的(LA)分离病毒,并了解差异 在CD4中,亲和力影响细胞的向向性。世界上第一个 研究人员的三个具体目标是定量研究吸附 以及PR和LA T细胞嗜性HIV分离株对CD4- 阳性细胞使用具有不同数量的CD4的细胞克隆。这个 作者建议研究HIV依恋步骤的动力学和 以确定每一步中CD4参与的顺序。他会的 识别CD_4以外限制LA附着的细胞因子(S) 病毒及其在感染途径中的位置。第二个目标 是利用分子克隆的PR和LA病毒的env基因和 具有降低CD4亲和力的突变病毒,并识别特征 控制病毒进入的离散步骤的包膜糖蛋白 小路。第三个目标是了解PR的吸收特性 病毒在疾病发展过程中不断变化。第四个也是最后一个目标 是开发一种新的系统来研究gp120-gp41-和cd4依赖的。 细胞-细胞融合,并用它来研究并可能克隆cDNA用于 细胞辅助因子。
英文摘要
DESCRIPTION: (Adapted from investigator's abstract) The goal of this project is to analyze quantitatively infections by primary patient (PR) and laboratory-adapted (LA) isolate viruses and to learn how differences in CD4 affinities affect cellular tropisms. The first of the investigator's three specific aims is to study quantitatively adsorption and penetration of PR and LA T cell-tropic HIV isolates into CD4- positive cells using cell clones with diverse amounts of CD4. The author proposes to study the kinetics of the steps of HIV attachment and to determine the order of CD4 involvement in each step. He will identify cellular factor(s) other than CD4 that limit attachment of LA viruses and their placement in the infection pathway. The second aim is to use molecularly cloned env genes of PR and LA viruses and of mutant viruses that have reduced CD4 affinities, and to identify features of env glycoproteins that control discrete steps of viral entry pathways. The third aim is to learn how absorptive properties of PR viruses change throughout disease progression. The fourth and last aim is to develop a novel system to study gp120- gp41- and CD4-dependent cell-cell fusion and to use it to study and possibly to clone cDNAs for cellular accessory factors.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Drug development for Vif-APOBEC3G in HIV-1/AIDS
Drug development for Vif-APOBEC3G in HIV-1/AIDS
Drug development for Vif-APOBEC3G in HIV-1/AIDS
Role of Vif in HIV-1 Replication/AIDS
海外基金